Desiree Smith - Plus Therapeutics Principal Controller
| PSTV Stock | USD 1.29 0.01 0.78% |
Insider
Desiree Smith is Principal Controller of Plus Therapeutics
| Age | 60 |
| Address | 4200 Marathon Boulevard, Austin, TX, United States, 78756 |
| Phone | 737 255 7194 |
| Web | https://plustherapeutics.com |
Plus Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.6939) % which means that it has lost $0.6939 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.225) %, meaning that it created substantial loss on money invested by shareholders. Plus Therapeutics' management efficiency ratios could be used to measure how well Plus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 10.37 in 2024, whereas Return On Tangible Assets are likely to drop (1.27) in 2024. Total Current Assets is likely to climb to about 17.1 M in 2024, whereas Total Assets are likely to drop slightly above 10.8 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Timothy Mayer | NextCure | 59 | |
| Nicole White | Assembly Biosciences | N/A | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| MBA BS | CytomX Therapeutics | 45 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Randall Schatzman | Bolt Biotherapeutics | 69 | |
| Sandeep MD | Instil Bio | 55 | |
| Ian Critchley | Spero Therapeutics | N/A | |
| Kathryn Falberg | Nuvation Bio | 60 | |
| Satyavrat CFA | Spero Therapeutics | 51 | |
| Robert Coutts | Achilles Therapeutics PLC | 40 | |
| BSc FRCPath | Achilles Therapeutics PLC | 59 | |
| Ming Yin | Bolt Biotherapeutics | N/A | |
| MBA MD | Cullinan Oncology LLC | 51 | |
| Michael MSBA | NextCure | 63 | |
| Lieping MD | NextCure | 67 | |
| Michelle Doig | Nuvation Bio | 46 | |
| AO FRACP | Assembly Biosciences | 65 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Christopher Ogden | CytomX Therapeutics | 40 | |
| Tharaknath Rao | Assembly Biosciences | N/A | |
Management Performance
| Return On Equity | -5.22 | ||||
| Return On Asset | -0.69 |
Plus Therapeutics Leadership Team
Elected by the shareholders, the Plus Therapeutics' board of directors comprises two types of representatives: Plus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Plus. The board's role is to monitor Plus Therapeutics' management team and ensure that shareholders' interests are well served. Plus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Plus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, CEO President | ||
| John Fraser, Chief Scientist | ||
| Gary CPA, Advisor | ||
| MS MBA, New Strategy | ||
| Marc MD, CEO Pres | ||
| Desiree Smith, Principal Controller | ||
| Andrew Sims, VP CFO | ||
| Andrew CPA, VP CFO | ||
| FACNP FACP, Chief VP |
Plus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Plus Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.22 | ||||
| Return On Asset | -0.69 | ||||
| Profit Margin | (2.40) % | ||||
| Operating Margin | (2.89) % | ||||
| Current Valuation | 6.16 M | ||||
| Shares Outstanding | 5.9 M | ||||
| Shares Owned By Insiders | 2.34 % | ||||
| Shares Owned By Institutions | 11.30 % | ||||
| Number Of Shares Shorted | 103.98 K | ||||
| Price To Book | 3.76 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.